1 study found for:    "methodist hospital" | Open Studies | "Adenomyoepithelioma" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
Conditions: Endometrial Clear Cell Adenocarcinoma;   Estrogen Receptor Negative;   Ovarian Clear Cell Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Dasatinib;   Other: Laboratory Biomarker Analysis

Indicates status has not been verified in more than two years